We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ingenuity Expands Scope of Licensing Agreement with Sanofi-Aventis

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Ingenuity Expands Scope of Licensing Agreement with Sanofi-Aventis"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Ingenuity Systems has announced that they have expanded the terms of their existing agreement with sanofi-aventis US, Inc. for access to Ingenuity Content and Ingenuity Pathways Analysis software.

Ingenuity Pathways Analysis is a web-delivered software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.

Ingenuity Pathways Analysis supports analysis of high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.

"Sanofi-aventis was one of the earliest adopters of Ingenuity technology and we are very pleased that we have been able to expand our relationship with this terrific team year after year," stated Peter DiLaura, Vice President, Sales and Customer Support.

"The Ingenuity product line enables IPA users to understand complex biology within their research, in addition to supporting the Bioinformatics team to further develop robust and proprietary computational solutions."

Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available online.